65,437 trials
Dementia · Cognitive Impairment · Mild Cognitive Impairment
Primary: New Occurrence in Dementia Care-A Composite Endpoint Including New Cognitive Diagnoses, Laboratory Investigations Related to Cognitive Impairment, New Dementia…
Obesity, Severe · Cesarean Section
Primary: Composite Wound Complication at Hospital Discharge and 2 Weeks Postpartum — 8; 5; 15; 16 Participants
Amyotrophic Lateral Sclerosis
Primary: Percent Change in HERV-K Level — -30.7 Percent change
Anxiety Disorders
Primary: Change in Percent of Correct Button Presses During Threat Compared to the Safe Condition (AAST) — -0.016; 0.008 Percentage of accurate responses
End Stage Renal Disease · Olfactory Disorders
Primary: Change From Baseline in Smell Identification Test Score at 6 Weeks — 4 units on a scale
Dental Implants
Primary: Difference in Implant Failure Rate Between Parallel Sided and Tapered Dental Implants at 5 Years — 1; 2 Participants — p=0.63
Spinal Cord Injury
Primary: Spinal Cord Injury Quality of Life Questionnaire (SCI QL-23 — 48.2 score on a scale
Erectile Dysfunction
Primary: Number of Participants Achieving MCID in IIEF-EF. — 14; 15; 10; 13 Participants
Narcolepsy
Primary: Change in Weekly Rate of Cataplexy Attacks — 0.98 cataplexy attacks per week
Depressive Symptoms · Quality of Life
Primary: Patient Health Questionnaire-8 Adolescent — 6.17; 9.43; 6.80; 8.29 units on a scale
Monkeypox
Primary: Vaccinia Virus Specific Plaque Reduction Neutralization Test (PRNT) Geometric Mean Titer (GMT) at Day 43 — 203.2; 113.2; 288.9 titer — p=0.045
Frailty
Primary: Change From Baseline Mediterranean Diet (MED) Adherence Score at 3 Months — 2.63; -0.29 score on a scale
Associative Memory in Healthy Subjects
Primary: A Computerized Verbal Paired-associate Memory Task Will be Used to Assess Memory Performance. — 38.036; 24.65; 52.93; 58.93 percentage of words learned/remembered
Overweight · Obesity · Diabetes Mellitus, Type 2
Primary: Pharmacokinetics (PK): Area Under the Concentration Time Curve From Time Zero to Time T, Where T is the Last Time Point With a Measurable Concentration [ AUC(0-tlast)]…
Mantle-Cell Lymphoma
Primary: Phase I: Dose Limiting Toxicities (DLT) Rate — 3; 5; 0; 1 Participants